The present invention provides a chimeric cytokine receptor (CCR) comprising: (i) an exodomain which binds to an intracellular ligand which is released from a cell as a result of necrosis; and (ii) a cytokine receptor endodomain.

The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.

The present invention relates to compositions and methods for generating RNA Chimeric Antigen Receptor (CAR) transfected T cells. The RNA-engineered T cells can be used in adoptive therapy to treat cancer.

The present invention relates to multispecific antibodies comprising at least three antigen binding sites wherein the third binding site is disulfide stabilized by introduction of cysteine, method for their production, pharmaceutical compositions containing said antibodies and uses thereof.

Compositions and methods for targeted treatment of cancer are disclosed. In particular, the invention relates to methods of targeting anti-cancer therapy to cells exhibiting aberrant signaling associated with cancer pathogenesis by administering synthetic signaling proteins that couple detection of an oncogenic signal to release of therapeutic agents into cancerous cells.

The present invention provides a chimeric receptor which comprises: a ligand-binding exodomain; and an endodomain which comprises: (i) a cytokine receptor endodomain; and (ii) an intracellular T cell signalling domain.

The present invention includes compositions, methods and kits for the real-time detection of transcription and translation in live cells, tissues and organisms. The present invention further provides method for the rapid sequencing of nucleic acids without using conventional sequencing techniques or reactions.

The present disclosure provides a method for endogenously tagging an endogenous protein in a cell, and a cell comprising an endogenously tagged protein. Also described are cells produced using such a method and a kit comprising a cell having tagged endogenous protein.

The present invention provides methods for using endogenous transcriptional control systems to regulate the expression of heterologous protein(s). In particular, targeted genome editing is used to integrate a sequence encoding the heterologous protein(s) in-frame with an endogenous coding sequence such that the expression of the heterologous and endogenous sequences is regulated by the endogenous control system.

The present invention relates to an isolated Pyk2-derived peptide comprising a consensus proline-rich region 2 (PRR2) sequence, wherein the consensus PRR2 sequence is PxxPx(R/K)P(K/R)(Y/W/F) in which x stands for any amino acid; and the peptide is capable of inhibiting metastasis by binding to a Src homology 3 (SH3) domain of cortactin. The present invention further provides methods of treating cancer and for preventing or inhibiting cancer invasion and/or metastasis by administering the isolated Pyk2-derived peptide of the invention, optionally in combination with an anti-cancer agent.